A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy
about
Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: an increasing problemMicrobiological and clinical aspects of infection associated with Stenotrophomonas maltophiliaUpdate on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic optionsCloning and characterization of SmeDEF, a novel multidrug efflux pump from Stenotrophomonas maltophilia.Cotrimoxazole - optimal dosing in the critically ill.Multiple antibiotic resistance in Stenotrophomonas maltophilia: involvement of a multidrug efflux system.Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistanceStenotrophomonas maltophilia infections in a general hospital: patient characteristics, antimicrobial susceptibility, and treatment outcome.Stenotrophomonas maltophilia endocarditis: a systematic review.Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis.Current strategies for the prevention and management of central line-associated bloodstream infections.Stenotrophomonas maltophilia in Lower Respiratory Tract Infections.Plasmid-mediated dissemination of the metallo-beta-lactamase gene blaIMP among clinically isolated strains of Serratia marcescens.In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia.Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenemStenotrophomonas maltophilia: emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber modelComparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rodsIn vitro activities of beta-lactam-beta-lactamase inhibitor combinations against Stenotrophomonas maltophilia: correlation between methods for testing inhibitory activity, time-kill curves, and bactericidal activityAntibiogram of Stenotrophomonas maltophilia Isolated From Nkonkobe Municipality, Eastern Cape Province, South Africa.Novel nosocomial infections by Stenotrophomonas maltophilia: first reported case from Lucknow, North India.Antimicrobial susceptibility of Stenotrophomonas maltophilia isolates from a Korean tertiary care hospital.Disseminated soft tissue infection and sepsis with Stenotrophomonas maltophilia in a bone marrow transplant patient.Comparison of E test and agar dilution for antimicrobial susceptibility testing of Stenotrophomonas (Xanthomonas) maltophilia.Antimicrobial susceptibility of stenotrophomonas maltophilia isolates from Korea, and the activity of antimicrobial combinations against the isolates.Antimicrobial therapy for Stenotrophomonas maltophilia infections.Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer.Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review.Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections.Levofloxacin and sparfloxacin: new quinolone antibiotics.Life-threatening hemorrhagic pneumonia caused by Stenotrophomonas maltophilia in the treatment of hematologic diseases.Current Situation of Antimicrobial Resistance and Genetic Differences in Stenotrophomonas maltophilia Complex Isolates by Multilocus Variable Number of Tandem Repeat Analysis.In vitro activities of membrane-active peptides alone and in combination with clinically used antimicrobial agents against Stenotrophomonas maltophilia.Antimicrobial activities of gatifloxacin against nosocomial isolates of Stenotrophomonas maltophilia measured by MIC and time-kill studies.Role of phosphoglucomutase of Stenotrophomonas maltophilia in lipopolysaccharide biosynthesis, virulence, and antibiotic resistance.Multiple antibiotic resistance in Stenotrophomonas maltophilia.Sequence analysis and enzyme kinetics of the L2 serine beta-lactamase from Stenotrophomonas maltophilia.In Vitro and In Vivo Control of Secondary Bacterial Infection Caused by Leishmania major.Biofilm formation by Stenotrophomonas maltophilia: modulation by quinolones, trimethoprim-sulfamethoxazole, and ceftazidime.Nonrespiratory Stenotrophomonas maltophilia infection at a children's hospital.Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model.
P2860
Q21245789-168CA84D-8B87-41EF-82F4-307FCC70F042Q24533461-08B0071A-A926-4ECE-8BD3-5E67DC1DF3D7Q26782924-0D7DFEFE-600B-471A-B895-38BF51254F5BQ30944576-51DF79A0-DF1A-43C9-8F05-C15FF5730463Q33652427-99F56575-6AB6-48A4-ADEB-080F5EE9B7E9Q33978663-EF92CB5C-C017-44B8-B9EC-D259D473511BQ34102811-0BE955F9-9ECB-4503-BDB1-A520B2D40FD9Q34279948-EC0EECE0-D03E-410B-A7BC-71811A788ADEQ34543262-C83D017E-355F-4BF5-B8FE-5AA4F8132EE0Q35005445-4E7235A6-EC45-41D0-B938-F911C3875D5EQ35026591-76126592-E7E9-40F8-955F-175EDA3A39CBQ35046315-69443C83-72A2-4495-A4EC-331C3736CE3DQ35112955-E66BCB67-6277-482B-B806-DB349507D7C5Q35119342-253B1A82-194E-499C-88CA-AA6CD1358FFDQ35123308-5CAB93EA-A359-4BB2-A6AD-E91D3A273933Q35130359-1BC5CF21-E4E9-4BF1-AD0B-8AD3CF2ED704Q35137076-6B9DF371-DD39-4A55-8011-6498C0EF167AQ35139268-E051AF12-B74C-4897-B1AA-777CEA45E8E5Q35148622-6688DBA7-7737-4B64-8159-4BF4C293589CQ35639000-7DB59D7B-C860-487D-BB1C-BF96AECD72B0Q35767386-4ADA1FB6-537B-48A4-AE6B-B03AF304DA13Q35891538-C0B070C4-2488-42FA-BF5C-1A64DE53786CQ36522459-54262120-CAE8-43D9-937D-FE84169382B1Q36536350-DC487E94-BF5A-4DA4-84BF-F3811A8FC506Q36749895-19CF43D0-C692-44F2-820D-A327F87604EAQ37055211-F81C808A-007C-4017-B03C-86AD1C4BCCD7Q37229067-5857E003-D52E-49C9-B75E-A991233EE0ACQ37544504-966ECA1A-EEF1-4CAB-AAF1-930AA1AABB44Q37881273-AD9EEABA-ECC2-419E-9ABD-98204BA93102Q38188881-83286B01-0BD3-48CD-A724-FD113B948422Q39054640-00515E65-62A9-4E39-8E34-19A25B212DAEQ39474230-1F834703-8E2E-458C-965E-DAB2B7783BD3Q39477842-72B03BD3-6BB3-4119-8C9F-3EE1D665DBFEQ39755193-548B0B65-FA2A-457A-B0BB-04A8B103FF37Q39784190-360B1EBA-E63E-4E9E-9382-D13CCF6D25BDQ39784489-A329F7FE-1D9C-4D4A-AB6F-65477C5D2C61Q40136470-CC6734F9-046F-4DCE-8412-FAE5A6416567Q40410432-3D6E1ED5-BE18-4C24-B630-71A370A502E6Q40611559-2FD7F703-C21D-4ABC-8C7E-4FD39A8D43F2Q40621865-3F493A5E-B49B-43D2-AABB-4A2A6340AF08
P2860
A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy
description
1994 nî lūn-bûn
@nan
1994 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի մարտին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
A changing pattern of suscepti ...... ents: implications for therapy
@ast
A changing pattern of suscepti ...... ents: implications for therapy
@en
type
label
A changing pattern of suscepti ...... ents: implications for therapy
@ast
A changing pattern of suscepti ...... ents: implications for therapy
@en
prefLabel
A changing pattern of suscepti ...... ents: implications for therapy
@ast
A changing pattern of suscepti ...... ents: implications for therapy
@en
P2093
P2860
P356
P1476
A changing pattern of suscepti ...... ents: implications for therapy
@en
P2093
P2860
P304
P356
10.1128/AAC.38.3.624
P407
P577
1994-03-01T00:00:00Z